Pharming Group Appoints New Supervisory Board Member
Ticker: PHAR · Form: 6-K · Filed: 2025-09-02T00:00:00.000Z
Sentiment: neutral
Topics: governance, board-appointment
TL;DR
Pharming Group adds Kenne to its Supervisory Board, boosting pharma expertise.
AI Summary
Pharming Group N.V. announced on September 2, 2025, the appointment of Kenne as a new member of its Supervisory Board. Kenne brings extensive experience in the pharmaceutical industry, which is expected to be valuable to the company's strategic direction.
Why It Matters
The addition of a new board member with relevant industry experience can signal a strategic shift or a strengthening of governance for Pharming Group.
Risk Assessment
Risk Level: low — The appointment of a board member is a routine corporate governance event with no immediate financial or operational risk indicated.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- Kenne (person) — Appointed to Supervisory Board
- September 2, 2025 (date) — Announcement Date
FAQ
Who is Kenne and what is their background?
The filing states Kenne has been appointed to the Supervisory Board, implying relevant experience, but does not provide specific details about Kenne's background in this document.
What is the role of the Supervisory Board at Pharming Group N.V.?
The filing does not explicitly detail the role of the Supervisory Board, but it is a common governance body in European companies responsible for oversight.
When was this appointment officially made?
The press release furnished as Exhibit 99.1 is dated September 2, 2025, indicating the announcement date.
Is this a change in executive leadership or a board position?
This is an appointment to the Supervisory Board, which is a governance and oversight role, not an executive management position.
What other exhibits are included with this 6-K filing?
The filing indicates that Exhibit 99.1 is a press release of Pharming Group N.V. dated September 2, 2025.
From the Filing
0001828316-25-000039.txt : 20250902 0001828316-25-000039.hdr.sgml : 20250902 20250902060530 ACCESSION NUMBER: 0001828316-25-000039 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250902 FILED AS OF DATE: 20250902 DATE AS OF CHANGE: 20250902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 251282800 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroupappointskenne.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated September 2, 2025. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group appoints Kenneth Lynard as Chief Financial Officer SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: September 2, 2025 Pharming Group appoints Kenneth Lynard as Chief Financial Officer Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, recognized for driving financial and operational transformation across complex, multinational organizations. His appointment follows our strong first half 2025 financial results and marks an important step in strengthening our financial leadership as we continue to execute on our growth strategy. Fabrice Chouraqui, Chief Executive Officer, commented: “We are delighted to welcome Kenneth to Pharming at a pivotal stage in our growth. Kenneth brings broad finance leadership capabilities from both established industry leaders and dynamic growth-stage companies, and operational experience in both the U.S. and EU. His strong value creation mindset, shaped by experience with companies backed by leading private equity firms, will be extremely valuable as we continue to advance our vision of building a leading global rare disease company.” Most recently, Mr. Lynard served as CFO of Schoeller Allibert and Zentiva, a European pharmaceutical company. He previously served as CFO at Affidea, and notably worked for Gilead Sciences, a leading US-based biopharmaceutical company, as Senior Vice President and CFO, Global Commer